OrbiMed’s Aurinia Pharmaceuticals AUPH Stock Holding History

OrbiMed’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-6,069,032	Closed	-$78.7M	–	176
2021 Q2	$78.7M	Hold	6,069,032	–	–	0.8%	41
2021 Q1	$78.8M	Buy	6,069,032 +1,315,032	+28%	+$19.1M	0.74%	42
2020 Q4	$65.7M	Hold	4,754,000	–	–	0.58%	49
2020 Q3	$70M	Buy	4,754,000 +3,557,653	+297%	+$51.5M	0.88%	34
2020 Q2	$19.4M	Sell	1,196,347 -140,200	-10%	-$2.24M	0.27%	78
2020 Q1	$19.4M	Sell	1,336,547 -1,008,900	-43%	-$17.8M	0.33%	67
2019 Q4	$47.5M	Sell	2,345,447 -1,185,555	-34%	-$10.9M	0.68%	46
2019 Q3	$18.9M	Hold	3,531,002	–	–	0.36%	67
2019 Q2	$23.2M	Buy	3,531,002 +381,192	+12%	+$2.43M	0.36%	63
2019 Q1	$20.5M	Buy	+3,149,810	New	+$20.9M	0.32%	73
2018 Q3	–	Sell	-167,419	Closed	-$943K	–	154
2018 Q2	$943K	Sell	167,419 -458,856	-73%	-$2.56M	0.01%	140
2018 Q1	$3.25M	Sell	626,275 -1,171,125	-65%	-$6.27M	0.04%	127
2017 Q4	$8.14M	Hold	1,797,400	–	–	0.1%	108
2017 Q3	$11.3M	Hold	1,797,400	–	–	0.11%	104
2017 Q2	$11M	Hold	1,797,400	–	–	0.12%	97
2017 Q1	$13.2M	Buy	+1,797,400	New	+$8.3M	0.15%	88

Other funds holding AUPH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KPWS

Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $23.5B AUM 33.24% 1-Year Est. Return

OrbiMed's AUPH Position: Q3 2021 in Review

OrbiMed sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2021, closing a stake of 6,069,032 shares — an estimated $78.7M sold.

OrbiMed first reported a position in AUPH in Q1 2017 and held it in 16 quarters. The position peaked at $78.8M in Q1 2021. 167 funds tracked by Wall St. Rank hold AUPH as of Q3 2021.

OrbiMed reported no remaining Aurinia Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
OrbiMed sold 6,069,032 Aurinia Pharmaceuticals shares in Q3 2021, an estimated $78.7M.
OrbiMed first reported a position in Aurinia Pharmaceuticals in Q1 2017 and held it in 16 quarters.
OrbiMed's Aurinia Pharmaceuticals position peaked at $78.8M in Q1 2021.
167 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2021.

Based on OrbiMed's 13F filing for Q3 2021, filed 15 Nov 2021.